Russ Conroy

Eye-related adverse effects after treatment for relapsed/refractory multiple myeloma in DREAMM-7 appear manageable with dose and schedule changes.

Phase 2 data show that vaccination with PolyPEPI1018 may enhance the efficacy of atezolizumab in those with microsatellite stable metastatic CRC.

Triplet therapies containing belantamab mafodotin may fulfill an unmet need for patients with multiple myeloma following the first relapse.

The FDA has set a new Prescription Drug User Fee Act date of November 9, 2024, for zolbetuximab in this gastric cancer population.

Findings from the TRANSCEND NHL 001 trial support the FDA approval of lisocabtagene maraleucel in relapsed/refractory mantle cell lymphoma.

The FDA has set a Prescription Drug User Fee Act date of November 29, 2024, for zanidatamab in this biliary tract cancer population.

The FDA has set a Prescription Drug User Fee Act date of November 27, 2024, for the inavolisib-based combination in this breast cancer population.

Data from the phase 1/2a AFM24-102 trial support the fast track designation for the AFM24 combination in EGFR wild-type non–small cell lung cancer.

Investigators plan to present additional findings from the phase 3 TROPION-Lung01 trial at a future medical meeting.

The FDA has set a Prescription Drug User Fee Act Date of September 27, 2024, for the isatuximab combination in transplant-ineligible NDMM.

Data support revisiting goals of care conversations with patients with very advanced cancer who have significantly progressed with their disease.

Treatment with complete mesocolic excision appears to reduce the length of hospital stay compared with conventional surgery in right colon cancer.

Data from the phase 2 RAMP 201 trial may support the potential accelerated approval of avutometinib/defactinib in KRAS-mutated LGSOC.

Findings may support bilateral mastectomy as an alternative for symmetry following unilateral mastectomy for breast cancer.

Investigators aim to identify a clinically useful and safe dose of Illuminare-1 for future studies in surgical cancer care.

Higher response rates with T-DXd occurred in patients with gastric cancer and plasma HER2 amplification in circulating tumor DNA in the DESTINY-Gatric01 trial.

Data from the ALLELE trial support the application for tabelecleucel in patients with EBV-positive post-transplant lymphoproliferative disease.

Data from the INAVO120 trial support the breakthrough therapy designation for inavolisib in PIK3CA-mutated, HR-positive, HER2-negative breast cancer.

Developers voluntarily request withdrawal of accelerated approval status for infigratinib as a treatment for FGFR2-positive cholangiocarcinoma.

The agency issues a complete response letter for the combination due to deficiencies associated with a manufacturing site inspection.

A reduced dosing duration of venetoclax plus hypomethylating agents may be appropriate for elderly patients with acute myeloid leukemia.

Data from the phase 1/2 ALKOVE-1 trial support the breakthrough therapy designation for NVL-655 in advanced ALK-positive non–small cell lung cancer.

Safety data further support datopotamab deruxtecan as a new treatment option in metastatic hormone receptor–positive, HER2-negative breast cancer.

Data from the TRANSCEND-FL trial support the accelerated approval of lisocabtagene maraleucel in relapsed/refractory follicular lymphoma.

Alternative treatment strategies may be necessary for a high-risk population of patients with acute myeloid leukemia and residual FLT3-ITD.

Data from a phase 1/2 trial support the FDA breakthrough therapy designation for petosemtamab in recurrent head and neck squamous cell carcinoma.

Approval of the self-collection solution may reduce barriers to sample collection and increase access to cervical cancer screening.

Patients with cancer who underwent surgery during the COVID-19 pandemic were also more likely to have respiratory complications.

The phase 3 KeyVibe-010 trial is unlikely to meet its primary end point of recurrence-free survival due to a high rate of treatment discontinuation.

The progression-free survival end point was not met in the CheckMate -73L trial assessing patients with unresectable stage III non–small cell lung cancer.